By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Evotec today said that it has completed its acquisition of DeveloGen, a German biopharmaceutical discovery and development firm, in a deal worth up to €14 million ($17.9 million).

Hamburg, Germany-based Evotec inked the agreement to acquire DeveloGen in July. It said that as of closing of the deal, the sellers of 99.3 percent of DeveloGen's shares had transferred their shares to Evotec.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.